Form 4: CRISPR Therapeutics Director Maria Fardis Granted 13,000 Stock Options

CRISPR Therapeutics AG Director Maria Fardis has been granted 13,000 stock options with an exercise price of $38.57, aligning her interests with shareholder value.

Summary

• Maria Fardis, a Director at CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options on June 5, 2025.
• The options have an exercise price of $38.57 per share.
• The options will vest 100% in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the date of the 2026 Annual General Meeting of Shareholders.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Maria Fardis beneficially owns 13,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event, not indicative of significant operational changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector.

Future Outlook

The future outlook indicates that the granted stock options will vest over the next 12 months, with full vesting expected by June 2026 or the 2026 Annual General Meeting, providing a long-term incentive for the director.

Industry Context

The grant of stock options is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align interests with shareholders. This practice is standard for companies like CRISPR Therapeutics, which rely on innovation and long-term value creation.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a widely accepted practice across the biotechnology and broader corporate landscape, consistent with global benchmarks for executive and board remuneration.
• The vesting schedule, typically over one to four years, is also standard, designed to retain talent and encourage sustained performance. While specific comparable companies or projects are not detailed in this filing, the structure of this grant aligns with general industry norms for director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align their interests with shareholders, potentially leading to better long-term performance and value creation. However, it also represents potential future dilution if options are exercised.

Next Steps

• The stock options will begin vesting in 12 equal monthly installments starting June 30, 2025.
• The final vesting will occur by June 5, 2026, or the date of the 2026 Annual General Meeting of Shareholders, whichever is earlier.

Key Dates

Recommendation

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Form 4, Biotechnology